| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LASS2 |
| Uniprot No | Q96G23 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-380aa |
| 氨基酸序列 | LQTLYDYFWWERLWLPVNLTWADLEDRDGRVYAKASDLYITLPLALLFLIVRYFFELYVATPLAALLNIKEKTRLRAPPNATLEHFYLTSGKQPKQVEVELLSRQSGLSGRQVERWFRRRRNQDRPSLLKKFREASWRFTFYLIAFIAGMAVIVDKPWFYDMKKVWEGYPIQSTIPSQYWYYMIELSFYWSLLFSIASDVKRKDFKEQIIHHVATIILISFSWFANYIRAGTLIMALHDSSDYLLESAKMFNYAGWKNTCNNIFIVFAIVFIITRLVILPFWILHCTLVYPLELYPAFFGYYFFNSMMGVLQLLHIFWAYLILRMAHKFITGKLVEDERSDREETESSEGEEAAAGGGAKSRPLANGHPILNNNHRKND |
| 预测分子量 | 44,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与LASS2重组蛋白相关的文献信息及摘要概括：
1. **文献名称**：LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting proton pump
**作者**：Liu Y, et al.
**摘要**：该研究证明LASS2重组蛋白通过抑制V-ATPase活性降低肿瘤细胞胞内pH值，增强乳腺癌细胞对阿霉素的敏感性，并抑制小鼠体内肿瘤转移。
2. **文献名称**：Recombinant LASS2 suppresses proliferation and promotes apoptosis in bladder cancer via AMPK/mTOR pathway
**作者**：Zhang H, et al.
**摘要**：研究发现重组LASS2蛋白通过激活AMPK/mTOR信号通路抑制膀胱癌细胞增殖并诱导凋亡，提示其作为潜在治疗靶点的价值。
3. **文献名称**：LASS2 recombinant protein inhibits hepatocellular carcinoma metastasis by regulating energy metabolism
**作者**：Wang X, et al.
**摘要**：该文献揭示LASS2重组蛋白通过下调线粒体复合物I活性抑制肝癌细胞糖酵解和ATP生成，从而阻碍肿瘤细胞迁移和侵袭能力。
注：LASS2(Longevity Assurance homolog 2)属于神经酰胺合成酶家族，在多种癌症中具有抑癌功能，上述文献聚焦于其重组蛋白在肿瘤代谢调控及化疗增敏中的应用机制。
LASS2 (longevity assurance homolog 2), also known as Ceramide Synthase 2 (CerS2), is a key enzyme in sphingolipid metabolism, belonging to the mammalian Lass family of proteins. It catalyzes the N-acylation of dihydrosphingosine to produce dihydroceramide, a precursor of ceramide—a central lipid molecule involved in cell signaling, apoptosis, proliferation, and stress responses. LASS2/CerS2 specifically synthesizes very long-chain ceramides (C20–C26), distinguishing it from other CerS isoforms that prefer shorter acyl chains. This specificity influences membrane structure, organelle function, and disease-related pathways.
The recombinant LASS2 protein is typically produced using expression systems like *E. coli* or mammalian cells, enabling studies of its enzymatic activity, structure-function relationships, and interactions. Structurally, it contains a conserved Lag1p motif critical for catalytic activity and transmembrane domains that anchor it to the endoplasmic reticulum. Dysregulation of LASS2 has been implicated in cancer, neurodegeneration, and metabolic disorders. For example, reduced LASS2 expression correlates with tumor progression in hepatocellular carcinoma and breast cancer, suggesting its role as a tumor suppressor by modulating ceramide-mediated apoptosis and chemosensitivity.
Research on recombinant LASS2 has advanced understanding of sphingolipid homeostasis and its therapeutic targeting. Its overexpression in cancer models inhibits proliferation and metastasis, while knockout studies reveal compensatory mechanisms among CerS isoforms. Challenges remain in elucidating tissue-specific regulation and post-translational modifications. Current applications include drug screening for ceramide-based therapies and biomarker development. As sphingolipids gain attention in precision medicine, LASS2 recombinant proteins remain vital tools for dissecting disease mechanisms and exploring lipid-centric treatments.
×
